Toronto, ON — Orchard Benefits is proud to announce its selection as an official Online Ambassador for the 2025 TELUS Health Drug Trends Report, joining a select group of Canadian healthcare leaders helping to raise awareness about the most pressing trends in employee drug benefits.

The TELUS Health Drug Trends Report is one of Canada’s most trusted annual reports on private drug plan costs, utilization, and benefit plan management. Drawing on the claims data of over 15 million insured Canadians, the 2025 edition highlights critical developments in areas such as weight management, diabetes, biosimilar adoption, and cost management strategies.

As an Online Ambassador, Orchard Benefits will play a key role in helping employers, HR leaders, and benefit plan advisors across Canada better understand the evolving healthcare landscape. This partnership enables Orchard to amplify critical conversations around improving employee health, making informed coverage decisions, and identifying opportunities for cost savings.

At Orchard, we believe that informed decisions create stronger workplaces and healthier communities,” said Chris Gory, Founder of Orchard Benefits. “We’re excited to support the broader benefits community by sharing these valuable insights with our clients and network. ”

Key findings from the 2025 TELUS Health Drug Trends Report include:

• Weight management drugs became the fastest-growing category in 2024, fueled by the introduction of Wegovy in Canada and reflecting a broader recognition of obesity as a chronic condition.
  
• Diabetes drugs remained the top category for eligible claim amounts, with new treatment options expanding their reach.
  
• Biosimilar adoption surged, driven by provincial switching policies and offering meaningful savings for private drug plans.
  
• Regional drug cost differences persist across Canada, highlighting opportunities for employers to refine their benefit strategies. 

Orchard Benefits invites business leaders and HR teams to explore the findings and discover how they can future-proof their benefits plans. Learn more about the TELUS Health Drug Trends Report and explore additional insights.